A Phase 1/2 Open label trial of SL-401 in combination with Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
The purpose of this study is to find the safest effective dose of SL-401 (the study drug) that can be given to participants with multiple myeloma (MM) in combination with pomalidomide and dexamethasone. This study will also look at how the study drug with pomalidomide and dexamethasone stops or slows cancer cell growth and how the study drug enters and leaves the body. This study will also look at whether certain proteins in the blood and bone marrow might change after receiving the study drug and whether the study drug effects the cancer.
- Male or female patient who is at least 18 years of age.
- Diagnosed with multiple myeloma and have previously received at least 2 prior therapies, including a proteasome inhibitor (such as Velcade or Revlimid) and lenalidomide
- No prior treatment with pomalidomide
18 - 99
Healthy Volunteers Needed
Duration of Participation
It is anticipated that each participant may be in the study for about 6 – 7 months of treatment followed by up to one year of observation, although the amount of time that each patient will participate will vary, depending on potential side effects and the growth or shrinkage of the cancer.
Clinical Trials Information Line
Stemline Therapeutics, Inc.